Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu, Yukihiro Hasegawa, Yuki Sato, Yoshiki Negi, Tomohiro Oba, Toshiyuki Sumi, Hirokuni Hirata, et al. Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). Therapeutic advances in medical oncology. 2025. 17. 17588359251344010-17588359251344010
Yoshihiro Miyashita, Yosuke Hirotsu, Yuki Nagakubo, Hiroaki Kobayashi, Makoto Kawaguchi, Koki Hata, Ryota Saito, Yumiko Kakizaki, Toshiharu Tsutsui, Toshio Oyama, et al. Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers-Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test. JTO clinical and research reports. 2024. 5. 6. 100679-100679
Yuki Nagakubo, Yosuke Hirotsu, Mona Yoshino, Kenji Amemiya, Ryota Saito, Yumiko Kakizaki, Toshiharu Tsutsui, Yoshihiro Miyashita, Taichiro Goto, Masao Omata. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer. Scientific reports. 2024. 14. 1. 12480-12480